Adam Biczo

Adam Biczo

Auto-generated profile, based on publicly available information

Adam Biczo

National Center for Spinal Disorders and Buda Health Center

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2016 in Inflammation Research
Verified
Journal Article
Closed access
PDF file
SKSándor Katz
Sándor Katz
VZViktória Zsiros
Viktória Zsiros
NDNikolett Dóczi
Nikolett Dóczi
ASArnold Szabó
Arnold Szabó
ÁBÁdám Biczó
Ádám Biczó
AKAnna L. Kiss
Anna L. Kiss

31 July 2020 in Disability and Rehabilitation
Verified
Journal Article
Closed access
JSJulia Szita
Julia Szita
LKLaszlo Kiss
Laszlo Kiss
ABAdam Biczo
Adam Biczo
KFKatalin Feher
Katalin Feher
PVPeter P. Varga
Peter P. Varga
ALAron Lazary
Aron Lazary
The STarT Back Tool was developed to identify the specific modifiable prognostic factors for non-specific low back pain and to classify the patients into risk groups; low, medium and high risk of c...

1 January 2025 in Global Spine Journal
Verified
Journal Article
Open access
ABAdam Biczo
Adam Biczo
ASArjun Sahgal
Arjun Sahgal
JVJorrit-Jan Verlaan
Jorrit-Jan Verlaan
PSPatel Shreyaskumar
Patel Shreyaskumar
ZSZsolt Szoverfi
Zsolt Szoverfi
ALAron Lazary
Aron Lazary
Study Design: Systematic review. Objectives: The objective of this review paper was to summarize targeted molecular therapy options for spinal chordoma and chondrosarcoma, and to provide an update on the relevant clinical trials open for recruitment. Methods: A systematic review of the current literature was performed, according to PRISMA guidelines, to summarize the latest developments in non-surgical molecular treatment options for low grade malignant primary spinal tumours. We also summarize those actively recruiting clinical trials based on clinicaltrials.gov. Results: A total of 73 studies and completed clinical trials were reviewed. Twenty actively recruiting clinical trials (eight for chordoma and twelve for chondrosarcoma) were identified. Conclusions: There is a strong need to find new therapeutic options to complement surgical resection and radiation therapy, which remain the cornerstone of management. Targeted therapies against molecular pathways show promise as compared to conventional chemotherapy.

13 August 2022 in Heliyon
Verified
Journal Article
Open access
ABArpad Bozsodi
Arpad Bozsodi
BSBeáta Scholtz
Beáta Scholtz
GPGergo Papp
Gergo Papp
ZSZoltan Sapi
Zoltan Sapi
ABAdam Biczo
Adam Biczo
ALAron Lazary
Aron Lazary
Chordoma, the most frequent malignant primary spinal neoplasm, characterized by a high rate of recurrence, is an orphan disease where the clarification of the molecular oncogenesis would be crucial to developing new, effective therapies. Dysregulated expression of non-coding RNAs, especially microRNAs (miRNA) has a significant role in cancer development. Next-generation RNA sequencing (NGS) was used for the combinatorial analysis of mRNA-miRNA gene expression profiles in sacral chordoma and nucleus pulposus samples. Advanced bioinformatics workflow was applied to the data to predict miRNA-mRNA regulatory networks with altered activity in chordoma. A large set of significantly dysregulated miRNAs in chordoma and their differentially expressed target genes have been identified. Several molecular pathways related to tumorigenesis and the modulation of the immune system are predicted to be dysregulated due to aberrant miRNA expression in chordoma. We identified a gene set including key regulators of the Hippo pathway, which is targeted by differently expressed miRNAs, and validated their altered expression by RT-qPCR. These newly identified miRNA/RNA interactions are predicted to have a role in the self-renewal process of chordoma stem cells, which might sustain the high rate of recurrence for this tumor. Our results can significantly contribute to the designation of possible targets for the development of anti-chordoma therapies.